Back to Directory

Thucuma Sise

Email

sisetk@niaid.nih.gov

Phone

301-451-2775

Institution

NIH

Title

Pharmacist, Contractor

Address

Pharmaceutical Affairs Branch, Division of AIDS
5601 Fishers Lane
MSC#9829
Rockville, MD 20852

Request an Update

Affiliated Studies

P1101: Phase I/II Dose-Finding, Safety, Tolerance and Pharmacokinetics Study of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in HIV-infected and TB Co-infected Infants and Children

DAIDS Number

11831

Research Area

Treatment

Study Status

Concluded

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) Given in Combination with an Individualized Rifampin-Resistant Tuberculosis (RR-TB) Therapy in Infants, Children and Adolescents with RR-TB Disease, Living with or without HIV

DAIDS Number

11884

Research Area

Tuberculosis

Study Status

Closed to Accrual

P1072: Safety and Immunogenicity of a Live, Attenuated, Rotavirus Vaccine (RotaTeq™) in HIV-1 Infected and Uninfected Children Born to HIV-1 Infected Mothers

DAIDS Number

10638

Research Area

Complications & Comorbidities

Study Status

Concluded

P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir

DAIDS Number

11773

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

DAIDS Number

34150

Research Area

Treatment

Study Status

Concluded

Show All